Search Department of Consumer Protection Filtered Topic Search

Press Releases

05/30/2012

Adderall 30 mg Tablets: Counterfeit Online Product Contains Wrong Active Ingredients

HARTFORD, May 30  -- Consumers who take Adderall and purchase this medication over the Internet should know that the Food and Drug Administration (FDA) has identified a counterfeit version of Teva Pharmaceutical Industries’ Adderall 30 milligram tablets that was sold on the Internet, the Department of Consumer Protection announced today.

The FDA’s preliminary laboratory tests revealed that the counterfeit version of Adderall contained the wrong active ingredients. Adderall contains four active ingredients – dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate. Instead of these active ingredients, the counterfeit product contained tramadol and acetaminophen, which are ingredients in medicines used to treat acute pain.

Adderall, which is approved to treat attention deficit hyperactivity disorders (ADHD) and narcolepsy, is a prescription drug classified as a controlled substance – special controls are required for dispensing this medication.

The counterfeit Adderall tablets are round, white and do not have any type of markings, such as letters or numbers. In contrast, authentic Adderall 30 mg tablets produced by Teva are round, orange/peach, and scored tablets with "dp" embossed on one side and "30" on the other side of the tablet.

Authentic Adderall:  

authentic

 Counterfeit Adderall: 

  fake

The Adderall 30 mg product may be counterfeit if:

1. The product comes in a blister package.

2. There are misspellings on the package.

 

  • “NDS” instead of “NDC”
  • “Aspartrte” instead of “Aspartate”
  • “Singel” instead of “Single”
3. The tablets are white, round and smooth.

4. The tablets have no markings on them.

Anyone who believes they have the counterfeit version of Teva’s Adderall 30 mg tablets should avoid or stop taking the product and talk to their health care professional about their condition and options for treatment.

-end-

 
Media Contact: Claudette Carveth
860-713-6022
Twitter: DCP on Twitter
Facebook: DCP on Facebook